Patents by Inventor Ulrich Hersel

Ulrich Hersel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10098930
    Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: October 16, 2018
    Assignee: Ascendis Pharma Endocrinology Division A/S
    Inventors: Harald Rau, Susanne Kindermann, Torben Lebmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogoe
  • Patent number: 10029015
    Abstract: A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on its surface. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: July 24, 2018
    Assignee: ASCENDIS PHARMA A/S
    Inventors: Ulrich Hersel, Harald Rau, Robert Schnepf, Dirk Vetter, Thomas Wegge
  • Patent number: 9913912
    Abstract: The present invention relates to carrier-linked prostanoid prodrugs of formula (I) Z1—(X0-L0-PG0)y (I), wherein Z1, X0, L0, PG0 and y have the meaning as indicated in the description and claims; pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising the same. It further relates to their use as medicaments, especially for treating, controlling, delaying or preventing pulmonary arterial hypertension.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: March 13, 2018
    Assignee: Ascendis Pharma A/S
    Inventors: Harald Rau, Guillaume Maitro, Ulrich Hersel, Oliver Keil, Thomas Wegge
  • Publication number: 20180042996
    Abstract: The present invention relates to a hydrogel-linked IL-Ira prodrug or pharmaceutically acceptable salt thereof. It further relates to a pharmaceutical composition comprising said hydrogel-linked IL-Ira prodrug, its use as medicament for the treatment of a IL-1 mediated disease, ways of application of such hydrogel-linked IL-Ira prodrugs or pharmaceutical compositions, and containers comprising the hydrogel-linked IL-Ira prodrugs or pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said hydrogel-linked IL-Ira prodrug or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 7, 2014
    Publication date: February 15, 2018
    Applicant: Ascendis Pharma Osteoarthritis Division A/S
    Inventors: Harald RAU, Joachim Zettler, Ulrich Hersel, Nora Kaluza, Mathias Krusch, Tobias Voigt
  • Patent number: 9872864
    Abstract: The present invention relates to sustained release compositions of prostacyclin, as well as uses thereof, in particular for the prevention and/or treatment of pulmonary arterial hypertension.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: January 23, 2018
    Assignee: Ascendis Pharma A/S
    Inventors: Kennett Sprogøe, Harald Rau, Ulrich Hersel, Thomas Wegge, Oliver Keil, Joachim Zettler
  • Publication number: 20170368189
    Abstract: The present invention relates to prodrugs of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising such CNP prodrugs and their uses. In an embodiment, the CNP prodrugs are conjugates of CNP peptides to poly(ethylene glycol) through a reversible linker.
    Type: Application
    Filed: January 8, 2016
    Publication date: December 28, 2017
    Inventors: Kennett SPROGØE, Ulrich HERSEL, Harald RAU, Thomas WEGGE, Frank FALTINGER, Felix CLEEMANN, Nora KALUZA, Ana BERNHARD, Annette BUBA, Tom WOODS
  • Publication number: 20170100490
    Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety; and -L is a non-biologically active linker moiety -L1 represented by formula (I): wherein the dashed line indicates the attachment to the amine of the biologically active moiety and wherein R1, R1a, R2, R2a, R3, R3a, X, X1, X2, X3 have the meaning as indicated in the description and the claims and wherein L1 is substituted with one to four groups L2-Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein L2 is a single chemical bond or a spacer; and Z is a carrier group. The invention also relates to A-L, wherein A is a leaving group, pharmaceutical composition comprising said prodrugs and their use as medicaments.
    Type: Application
    Filed: December 20, 2016
    Publication date: April 13, 2017
    Applicant: Ascendis Pharma A/S
    Inventors: Felix Cleeman, Ulrich Hersel, Silvia Kaden, Harald Rau, Thomas Wegge
  • Patent number: 9561287
    Abstract: The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: February 7, 2017
    Assignee: Ascendis Pharma A/S
    Inventors: Ulrich Hersel, Harald Rau, Torben Lessmann, Nicola Bisek, Guillaume Maitro, Kennett Sprogøe, Thomas Wegge, Oliver Keil, Joachim Zettler
  • Patent number: 9457066
    Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an insulin linker conjugate D-L, wherein D represents the insulin moiety; and -L is a non-biologically active linker moiety -L1 represented by formula (I), wherein the dashed line indicates the attachment to one of the amino groups of the insulin by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by insulin.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: October 4, 2016
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Harald Rau, Felix Cleemann, Ulrich Hersel, Silvia Kaden-Vagt, Torben Lessmann, Thomas Wegge
  • Publication number: 20160206702
    Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.
    Type: Application
    Filed: January 19, 2016
    Publication date: July 21, 2016
    Applicant: Ascendis Pharma Growth Disorders Division A/S
    Inventors: Harald Rau, Susanne Kindermann, Torben Lebmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogoe
  • Patent number: 9353170
    Abstract: Long-acting polymer exendin-4 or exendin agonist derivatives of the formula Pol-L-E are provided wherein Pol is a polymer, L is a releasing linker undergoing slow autohydrolysis and E is an exendin or exendin agonist. These exendin or exendin agonists are slowly released from Pol-L upon administration to a living organism. The derivatives are useful e.g. for the treatment of diabetes mellitus.
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: May 31, 2016
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Ulrich Hersel, Harald Rau, Dirk Vetter, Thomas Wegge
  • Publication number: 20160089448
    Abstract: A cascade carrier linked prodrug is described comprising a biologically active moiety and a masking group having at least one nucleophile and being distinct from the carrier.
    Type: Application
    Filed: December 10, 2015
    Publication date: March 31, 2016
    Inventors: Ulrich Hersel, Harald Rau, Robert Schnepf, Dirk Vetter, Thomas Wegge
  • Publication number: 20160089446
    Abstract: The present invention relates to a process for the preparation of a hydrogel suitable as carrier in a hydrogel-linked prodrug, to hydrogels obtainable from said process, the use of such hydrogel as a carrier in a hydrogel-linked prodrug and to hydrogel-linked prodrugs comprising a covalently conjugated hydrogel of the present invention. The hydrogel prodrug carrier has a reduced drug loading on the outside of the hydrogel carrier. This is achieved by reducing the number of functional groups of the hydrogel, in particular those at its surface.
    Type: Application
    Filed: April 16, 2014
    Publication date: March 31, 2016
    Applicant: Ascendis Pharma A/S
    Inventors: Ulrich HERSEL, Harald RAU, Burkhardt LAUFER, Joachim ZETTLER, Romy REIMANN
  • Publication number: 20160082123
    Abstract: The present invention relates to a process for the preparation of a hydrogel-linked prodrug releasing a tag moiety-biologically active moiety conjugate, to a hydrogel-linked prodrug releasing a tag moiety-bio logically active moiety conjugate obtainable by such process, to pharmaceutical compositions comprising said prodrug and their use as a medicament.
    Type: Application
    Filed: April 16, 2014
    Publication date: March 24, 2016
    Applicant: Ascendis Pharma A/S
    Inventors: Harald RAU, Nora KALUZA, Ulrich HERSEL, Thomas KNAPPE, Burkhardt LAUFER
  • Patent number: 9278139
    Abstract: The present invention relates to a terminal sterilization process for biodegradable PEG-based insoluble hydrogels using irradiation. The presence of a protective solvent ensures that the hydrogel remains intact with functionally preserved three-dimensional and physicochemical properties.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: March 8, 2016
    Assignee: Ascendis Pharma A/S
    Inventors: Harald Rau, Tobias Voigt, Ulrich Hersel
  • Patent number: 9272048
    Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: March 1, 2016
    Assignee: Ascendis Pharma Growth Disorders Division A/S
    Inventors: Harald Rau, Susanne Kinderman, Torben Lebmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogoe
  • Patent number: 9265723
    Abstract: The present invention relates to a pharmaceutical composition comprising an insulin compound in a concentration that is sufficient to maintain a therapeutically effective level of the insulin compound in blood plasma for at least 3 days characterized by having a pharmacokinetic profile in vivo with substantially no burst of the insulin compound. The present invention further relates to the use of an insulin compound for preparing said pharmaceutical composition as well as a kit of parts comprising said pharmaceutical composition.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: February 23, 2016
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Kennett Sprogoe, Felix Cleemann, Ulrich Hersel, Silvia Kaden-Vagt, Torben Lessmann, Harald Rau, Thomas Wegge
  • Patent number: 9238686
    Abstract: A cascade carrier linked prodrug is described comprising a biologically active moiety and a masking group having at least one nucleophile and being distinct from the carrier.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: January 19, 2016
    Assignee: Ascendis Pharma GmbH
    Inventors: Ulrich Hersel, Harald Rau, Robert Schnepf, Dirk Vetter, Thomas Wegge
  • Patent number: 9173953
    Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein an aromatic amine containing biologically active moiety is connected (bound) by an amido bound to a linker. The invention also relates to pharmaceutical compositions comprising said prodrugs and their use as medicaments.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: November 3, 2015
    Assignee: Ascendis Pharma AS
    Inventors: Harald Rau, Julia Baron, Ulrich Hersel, Mathias Krusch
  • Publication number: 20150306239
    Abstract: The present invention relates to carrier-linked prostanoid prodrugs of formula (I) Z1—(X0-L0-PG0)y (I), wherein Z1, X0, L0, PG0 and y have the meaning as indicated in the description and claims; pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising the same. It further relates to their use as medicaments, especially for treating, controlling, delaying or preventing pulmonary arterial hypertension.
    Type: Application
    Filed: December 6, 2013
    Publication date: October 29, 2015
    Applicant: ASCENDIS PHARMA A/S
    Inventors: Harald Rau, Guillaume Maitro, Ulrich Hersel, Oliver Keil, Thomas Wegge